Home > Resources > Whitepapers > Process PLM: The Future of Pharmaceutical Manufacturing

Process PLM: The Future of Pharmaceutical Manufacturing

It’s been over a dozen years since The Wall Street Journal famously observed that pharmaceutical manufacturing techniques lagged “far behind those of potato-chip and laundry-soap makers.”1 The same publication made a similarly stark observation just last year, contrasting the “cutting-edge science” driving new drug development with the industry’s long adherence to manufacturing processes “dating to the days of the steam engine.”

Spotlight

Pharma Consulting Group (PCG)

We are The Pharma Consulting Group. A leading provider of search, contingent and contract recruitment across the life sciences sector. We have expanded organically and through acquisition and in doing so have developed a business with the experience, networks and skill to deliver for you; whether you’re looking for a new member of your team, or a new challenge in your career.

OTHER WHITEPAPERS

The Ultimate Guide to Pharmaceutical Quality Managemen

whitePaper | October 20, 2022

When the first Nokia and Motorola cell phones that were affordable and small enough to fit in your pocket hit the market, they not only changed how we viewed phone technology but how we communicated.

Best practices in viral vector analytical characterization

whitePaper | December 13, 2022

Viral vectors are a critical part of the advanced therapies supply chain as they are used to introduce the gene of interest, whether that’s into a cell intended for therapeutic gene transfer or for direct viral-mediated gene transfer into the patient.

Artificial Intelligence in Drug Manufacturing

whitePaper | May 25, 2023

CDER’s mission is to ensure that human drugs are safe and effective, meet established quality standards, and are available to patients. To advance this mission, FDA’s Pharmaceutical Quality for the 21st Century Initiative promotes an efficient, agile, and flexible pharmaceutical manufacturing sector that reliably produces quality drugs without excessive regulatory oversight.